{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:39:14Z","timestamp":1792147154637,"version":"4.4.0"},"reference-count":167,"publisher":"The Company of Biologists","issue":"9","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Institute","award":["5R25CA020449"],"award-info":[{"award-number":["5R25CA020449"]}]},{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merus"},{"name":"Elevation Oncology"},{"DOI":"10.13039\/100016936","name":"Loxo Oncology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>The central nervous system (CNS) represents a site of sanctuary for many metastatic tumors when systemic therapies that control the primary tumor cannot effectively penetrate intracranial lesions. Non-small cell lung cancers (NSCLCs) are the most likely of all neoplasms to metastasize to the brain, with up to 60% of patients developing CNS metastases during the disease process. Targeted therapies such as tyrosine kinase inhibitors (TKIs) have helped reduce lung cancer mortality but vary considerably in their capacity to control CNS metastases. The ability of these therapies to effectively target lesions in the CNS depends on several of their pharmacokinetic properties, including blood\u2013brain barrier permeability, affinity for efflux transporters, and binding affinity for both plasma and brain tissue. Despite the existence of numerous preclinical models with which to characterize these properties, many targeted therapies have not been rigorously tested for CNS penetration during the discovery process, whereas some made it through preclinical testing despite poor brain penetration kinetics. Several TKIs have now been engineered with the characteristics of CNS-penetrant drugs, with clinical trials proving these efforts fruitful. This Review outlines the extent and variability of preclinical evidence for the efficacy of NSCLC-targeted therapies, which have been approved by the US Food and Drug Administration (FDA) or are in development, for treating CNS metastases, and how these data correlate with clinical outcomes.<\/jats:p>","DOI":"10.1242\/dmm.050836","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T10:30:31Z","timestamp":1727692231000},"source":"Crossref","is-referenced-by-count":8,"title":["Preclinical evaluation of targeted therapies for central nervous system metastases"],"prefix":"10.1242","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5159-019X","authenticated-orcid":false,"given":"Alexander J.","family":"Pfeil","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center 1 Department of Pathology and Laboratory Medicine , , New York, NY 10065 ,","place":["USA"]},{"name":"University of North Carolina School of Medicine 2 , Chapel Hill, NC 27514 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2683-6477","authenticated-orcid":false,"given":"Joshua D.","family":"Hale","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine 2 , Chapel Hill, NC 27514 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6669-8814","authenticated-orcid":false,"given":"Tiger S.","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine 2 , Chapel Hill, NC 27514 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Wakayama","sequence":"additional","affiliation":[{"name":"Taiho Pharmaceutical Co. Ltd. 3 3 , Okubo, Tsukuba, Ibaraki 300-2611 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Taiho Pharmaceutical Co. Ltd. 3 3 , Okubo, Tsukuba, Ibaraki 300-2611 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8073-8803","authenticated-orcid":false,"given":"Igor","family":"Odintsov","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School 4 Department of Pathology , , Boston, MA 021105 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5282-6889","authenticated-orcid":false,"given":"Romel","family":"Somwar","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center 1 Department of Pathology and Laboratory Medicine , , New York, NY 10065 ,","place":["USA"]},{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center 5 , New York, NY 10065 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"237","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"2024093010302369900_DMM050836C1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1124\/jpet.110.167601","article-title":"Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux","volume":"334","author":"Agarwal","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024093010302369900_DMM050836C2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S2213-2600(17)30378-8","article-title":"Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study","volume":"5","author":"Ahn","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"2024093010302369900_DMM050836C3","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/neuonc\/noac118","article-title":"Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions","volume":"24","author":"Aizer","year":"2022","journal-title":"Neuro Oncol."},{"key":"2024093010302369900_DMM050836C4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3892\/or.14.3.733","article-title":"Response to radiotherapy in brain metastases and survival of patients with non-small cell lung cancer","volume":"14","author":"Antoniou","year":"2005","journal-title":"Oncol. Rep."},{"key":"2024093010302369900_DMM050836C5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"2024093010302369900_DMM050836C6","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"2024093010302369900_DMM050836C7","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1093\/annonc\/mdr003","article-title":"Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)","volume":"22","author":"Barlesi","year":"2011","journal-title":"Ann. Oncol."},{"key":"2024093010302369900_DMM050836C8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/resp.12490","article-title":"Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC)","volume":"20","author":"Barr Kumarakulasinghe","year":"2015","journal-title":"Respirology"},{"key":"2024093010302369900_DMM050836C9","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1038\/s41598-021-81832-1","article-title":"Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases","volume":"11","author":"Baschnagel","year":"2021","journal-title":"Sci. Rep."},{"key":"2024093010302369900_DMM050836C10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","article-title":"Brain penetration of lorlatinib: cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer","volume":"15","author":"Bauer","year":"2020","journal-title":"Target. oncol."},{"key":"2024093010302369900_DMM050836C11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41568-019-0220-y","article-title":"Brain metastasis","volume":"20","author":"Boire","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"2024093010302369900_DMM050836C12","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1200\/JCO.20.00505","article-title":"Brigatinib versus crizotinib in advanced ALK inhibitor\u2013naive ALK-positive non\u2013small cell lung cancer: second interim analysis of the phase III ALTA-1L trial","volume":"38","author":"Camidge","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C13","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.3390\/cancers13174415","article-title":"RET inhibitors in non-small-cell lung cancer","volume":"13","author":"Cascetta","year":"2021","journal-title":"Cancers"},{"key":"2024093010302369900_DMM050836C14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.lungcan.2013.08.013","article-title":"Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis","volume":"82","author":"Chen","year":"2013","journal-title":"Lung Cancer"},{"key":"2024093010302369900_DMM050836C15","doi-asserted-by":"publisher","first-page":"115115","DOI":"10.1016\/j.ab.2023.115115","article-title":"Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients","volume":"669","author":"Chen","year":"2023","journal-title":"Anal. Biochem."},{"key":"2024093010302369900_DMM050836C16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: Past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C17","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-21-1838","article-title":"ASCEND-7: Efficacy and safety of ceritinib treatment in patients with ALK-positive non\u2013small cell lung cancer metastatic to the brain and\/or leptomeninges","volume":"28","author":"Chow","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"2024093010302369900_DMM050836C172","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/ijc.28475","article-title":"Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar","volume":"134","author":"Chuan Tang","year":"2014","journal-title":"Int. J. Cancer"},{"key":"2024093010302369900_DMM050836C18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1359-6446(03)02827-7","article-title":"In silico prediction of blood\u2013brain barrier permeation","volume":"8","author":"Clark","year":"2003","journal-title":"Drug Discov. Today"},{"key":"2024093010302369900_DMM050836C19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood\u2013brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2024093010302369900_DMM050836C20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000066520","article-title":"Front-line paclitaxel\/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer","volume":"64","author":"Cortes","year":"2002","journal-title":"Oncology"},{"key":"2024093010302369900_DMM050836C21","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C22","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical experience with crizotinib in patients with advanced ALK-rearranged non\u2013small-cell lung cancer and brain metastases","volume":"33","author":"Costa","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C23","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.7314\/APJCP.2015.16.10.4147","article-title":"Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities","volume":"16","author":"Daga","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2024093010302369900_DMM050836C24","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10585-013-9566-9","article-title":"In vivo animal models for studying brain metastasis: value and limitations","volume":"30","author":"Daphu","year":"2013","journal-title":"Clin. Exp. Metastasis"},{"key":"2024093010302369900_DMM050836C25","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1159\/000535172","article-title":"Cerebrospinal fluid concentration of the RET inhibitor pralsetinib: a case report","volume":"16","author":"De Jong","year":"2023","journal-title":"Case Rep. Oncol."},{"key":"2024093010302369900_DMM050836C26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10928-013-9301-9","article-title":"Utility of CSF in translational neuroscience","volume":"40","author":"de Lange","year":"2013","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"2024093010302369900_DMM050836C27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10637-010-9569-1","article-title":"Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP","volume":"30","author":"de Vries","year":"2012","journal-title":"Investig. New Drugs"},{"key":"2024093010302369900_DMM050836C28","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-06-2854","article-title":"The blood-brain barrier and cancer: transporters, treatment, and Trojan horses","volume":"13","author":"Deeken","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"2024093010302369900_DMM050836C29","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/S1470-2045(15)00077-7","article-title":"Genomic alterations in lung adenocarcinoma","volume":"16","author":"Devarakonda","year":"2015","journal-title":"Lancet Oncol."},{"key":"2024093010302369900_DMM050836C30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40265-023-01839-y","article-title":"Adagrasib: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"2024093010302369900_DMM050836C31","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.jtho.2019.08.059","article-title":"PL02. 08 registrational results of LIBRETTO-001: a phase 1\/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers","volume":"14","author":"Drilon","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"2024093010302369900_DMM050836C32","doi-asserted-by":"publisher","first-page":"e201617-e201617","DOI":"10.1001\/jamanetworkopen.2020.1617","article-title":"Assessment of effectiveness and safety of osimertinib for patients with intracranial metastatic disease: a systematic review and meta-analysis","volume":"3","author":"Erickson","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"2024093010302369900_DMM050836C33","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.ejca.2014.02.001","article-title":"Prospective screening for ALK: clinical features and outcome according to ALK status","volume":"50","author":"Fallet","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"2024093010302369900_DMM050836C34","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.2147\/OTT.S67586","article-title":"EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data","volume":"7","author":"Fan","year":"2014","journal-title":"OncoTargets Ther."},{"key":"2024093010302369900_DMM050836C35","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00280-015-2847-z","article-title":"Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: A self-controlled, pilot study","volume":"76","author":"Fang","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2024093010302369900_DMM050836C36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1124\/dmd.107.017434","article-title":"In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system","volume":"36","author":"Feng","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"2024093010302369900_DMM050836C37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3001","article-title":"Mouse models of advanced spontaneous metastasis for experimental therapeutics","volume":"11","author":"Francia","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"2024093010302369900_DMM050836C38","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1124\/dmd.108.026377","article-title":"Development of a high-throughput brain slice method for studying drug distribution in the central nervous system","volume":"37","author":"Frid\u00e9n","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"2024093010302369900_DMM050836C39","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1021\/jm901036q","article-title":"Structure\u2212 brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids","volume":"52","author":"Frid\u00e9n","year":"2009","journal-title":"J. Med. Chem."},{"key":"2024093010302369900_DMM050836C40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.lungcan.2021.11.020","article-title":"Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases","volume":"163","author":"Friese-Hamim","year":"2022","journal-title":"Lung Cancer"},{"key":"2024093010302369900_DMM050836C41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol."},{"key":"2024093010302369900_DMM050836C42","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","article-title":"Novel targets in non-small cell lung cancer: ROS1 and RET fusions","volume":"18","author":"Gainor","year":"2013","journal-title":"Oncologist"},{"key":"2024093010302369900_DMM050836C43","doi-asserted-by":"publisher","first-page":"9008","DOI":"10.1200\/JCO.2019.37.15_suppl.9008","article-title":"Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-Fusion+ non small cell lung cancer","volume":"37","author":"Gainor","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C44","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/jps.23901","article-title":"Establishment of optimized MDCK cell lines for reliable efflux transport studies","volume":"103","author":"Gartzke","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"2024093010302369900_DMM050836C45","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion\u2013positive non-small-cell lung cancer including as first-line therapy: Update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann. Oncol."},{"key":"2024093010302369900_DMM050836C46","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1023\/A:1012080106490","article-title":"Drug equilibration across the blood\u2014brain barrier-pharmacokinetic considerations based on the microdialysis method","volume":"14","author":"Hammarlund-Udenaes","year":"1997","journal-title":"Pharm. Res."},{"key":"2024093010302369900_DMM050836C47","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s11095-007-9502-2","article-title":"On the rate and extent of drug delivery to the brain","volume":"25","author":"Hammarlund-Udenaes","year":"2008","journal-title":"Pharm. Res."},{"key":"2024093010302369900_DMM050836C48","doi-asserted-by":"publisher","first-page":"10030","DOI":"10.1021\/acs.jmedchem.6b00618","article-title":"Small molecule kinase inhibitors for the treatment of brain cancer","volume":"59","author":"Heffron","year":"2016","journal-title":"J. Med. Chem."},{"key":"2024093010302369900_DMM050836C49","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/neuonc\/nox179","article-title":"Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels","volume":"20","author":"Heffron","year":"2018","journal-title":"Neuro Oncol."},{"key":"2024093010302369900_DMM050836C50","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1158\/1078-0432.CCR-12-0357","article-title":"The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non\u2013small cell lung cancer with EGFR mutations","volume":"18","author":"Heon","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"2024093010302369900_DMM050836C51","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jcpa.2015.12.001","article-title":"Spontaneously arising canine glioma as a potential model for human glioma","volume":"154","author":"Herranz","year":"2016","journal-title":"J. Comp. Pathol."},{"key":"2024093010302369900_DMM050836C52","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.21873\/anticanres.15347","article-title":"Large animal models of glioma: Current status and future prospects","volume":"41","author":"Hicks","year":"2021","journal-title":"Anticancer Res."},{"key":"2024093010302369900_DMM050836C53","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/JTO.0000000000000380","article-title":"Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)\u2013pretreated non\u2013small-cell lung cancer patients with brain metastases or leptomeningeal disease","volume":"10","author":"Hoffknecht","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"2024093010302369900_DMM050836C54","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.lungcan.2016.04.004","article-title":"EGFR mutation status on brain metastases from non-small cell lung cancer","volume":"96","author":"Hsu","year":"2016","journal-title":"Lung Cancer"},{"key":"2024093010302369900_DMM050836C55","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.lungcan.2013.08.016","article-title":"Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma","volume":"82","author":"Iuchi","year":"2013","journal-title":"Lung Cancer"},{"key":"2024093010302369900_DMM050836C56","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non\u2013small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"2024093010302369900_DMM050836C57","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jtho.2016.05.013","article-title":"EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases","volume":"11","author":"Jiang","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"2024093010302369900_DMM050836C58","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1021\/jm500261q","article-title":"Discovery of (10 R)-7-Amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4-(metheno) pyrazolo [4, 3-h][2, 5, 11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations","volume":"57","author":"Johnson","year":"2014","journal-title":"J. Med. Chem."},{"key":"2024093010302369900_DMM050836C59","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.21037\/tlcr-20-379","article-title":"The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer","volume":"9","author":"Jung","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"2024093010302369900_DMM050836C60","doi-asserted-by":"publisher","first-page":"102068","DOI":"10.1016\/j.esmoop.2023.102068","article-title":"Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study","volume":"8","author":"Jung","year":"2023","journal-title":"ESMO Open"},{"key":"2024093010302369900_DMM050836C61","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/jac\/dkn110","article-title":"Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect","volume":"61","author":"Kanellakopoulou","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"2024093010302369900_DMM050836C62","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.rmed.2013.11.020","article-title":"Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma","volume":"108","author":"Kang","year":"2014","journal-title":"Respir. Med."},{"key":"2024093010302369900_DMM050836C63","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"2024093010302369900_DMM050836C64","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00280-015-2759-y","article-title":"High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs","volume":"75","author":"Kawamura","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2024093010302369900_DMM050836C65","doi-asserted-by":"publisher","first-page":"9147","DOI":"10.1021\/acs.jmedchem.3c00746","article-title":"Discovery of AZD4747, a potent and selective inhibitor of mutant GTPase KRASG12C with demonstrable CNS penetration","volume":"66","author":"Kettle","year":"2023","journal-title":"J. Med. Chem."},{"key":"2024093010302369900_DMM050836C66","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.2012.46.0410","article-title":"On the merits and limitations of whole-brain radiation therapy","volume":"31","author":"Khan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C67","doi-asserted-by":"publisher","first-page":"100426","DOI":"10.1016\/j.dmpk.2021.100426","article-title":"Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse","volume":"42","author":"Kido","year":"2022","journal-title":"Drug Metab. Pharmacokinet"},{"key":"2024093010302369900_DMM050836C68","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nm.2072","article-title":"Real-time imaging reveals the single steps of brain metastasis formation","volume":"16","author":"Kienast","year":"2010","journal-title":"Nat. Med."},{"key":"2024093010302369900_DMM050836C69","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","article-title":"Intracranial and whole-body response of ceritinib in ALK inhibitor-na\u00efve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol."},{"key":"2024093010302369900_DMM050836C70","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1124\/dmd.118.084210","article-title":"Brain distribution of a panel of epidermal growth factor receptor inhibitors using cassette dosing in wild-type and Abcb1\/Abcg2-deficient mice","volume":"47","author":"Kim","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"2024093010302369900_DMM050836C71","doi-asserted-by":"publisher","first-page":"E3119","DOI":"10.1073\/pnas.1216078109","article-title":"Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases","volume":"109","author":"Kodack","year":"2012","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2024093010302369900_DMM050836C72","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1124\/jpet.111.180398","article-title":"Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate","volume":"339","author":"Kodaira","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024093010302369900_DMM050836C73","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00280-014-2578-6","article-title":"Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases","volume":"74","author":"Kodama","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2024093010302369900_DMM050836C74","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nm.2644","article-title":"KIF5B-RET fusions in lung adenocarcinoma","volume":"18","author":"Kohno","year":"2012","journal-title":"Nat. Med."},{"key":"2024093010302369900_DMM050836C75","doi-asserted-by":"publisher","first-page":"e1557","DOI":"10.1016\/j.wneu.2018.11.100","article-title":"Neurosurgical resection and stereotactic radiation versus stereotactic radiation alone in patients with a single or solitary brain metastasis","volume":"122","author":"Lamba","year":"2019","journal-title":"World Neurosurg"},{"key":"2024093010302369900_DMM050836C76","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","article-title":"Epidemiology of brain metastases and leptomeningeal disease","volume":"23","author":"Lamba","year":"2021","journal-title":"Neuro Oncol."},{"key":"2024093010302369900_DMM050836C77","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1290\/1071-2690(2002)038&lt;0401:CAAOAV&gt;2.0.CO;2","article-title":"Characterization and application of a vinblastine-selected Caco-2 cell line for evaluation of P-glycoprotein","volume":"38","author":"Laska","year":"2002","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"2024093010302369900_DMM050836C78","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C79","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/sj.bjc.6604213","article-title":"Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors","volume":"98","author":"Lemos","year":"2008","journal-title":"Br. J. Cancer"},{"key":"2024093010302369900_DMM050836C80","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"2024093010302369900_DMM050836C81","doi-asserted-by":"publisher","first-page":"101911","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"2024093010302369900_DMM050836C82","doi-asserted-by":"publisher","first-page":"e18065","DOI":"10.1200\/jco.2011.29.15_suppl.e18065","article-title":"The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis","volume":"29","author":"Li","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C83","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2174\/138920008783331077","article-title":"CSF as a surrogate for assessing CNS exposure: an industrial perspective","volume":"9","author":"Lin","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"2024093010302369900_DMM050836C84","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1124\/dmd.108.024125","article-title":"Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid","volume":"37","author":"Liu","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"2024093010302369900_DMM050836C85","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","article-title":"Heterogeneous blood\u2013tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer","volume":"16","author":"Lockman","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"2024093010302369900_DMM050836C86","doi-asserted-by":"publisher","first-page":"106137","DOI":"10.1016\/j.phrs.2022.106137","article-title":"ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a\/1b restrict its oral availability","volume":"178","author":"Loos","year":"2022","journal-title":"Pharmacol. Res."},{"key":"2024093010302369900_DMM050836C87","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbcan.2016.12.001","article-title":"Brain metastasis: Unique challenges and open opportunities","volume":"1867","author":"Lowery","year":"2017","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2024093010302369900_DMM050836C88","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1158\/1535-7163.MCT-07-2250","article-title":"Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1\u2212\/\u2212\/Mdr1a\/1b\u2212\/\u2212(triple-knockout) and wild-type mice","volume":"7","author":"Marchetti","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"2024093010302369900_DMM050836C89","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2020.12.002","article-title":"Brain metastasis models: What should we aim to achieve better treatments?","volume":"169","author":"Masmudi-Mart\u00edn","year":"2021","journal-title":"Adv. Drug Delivery. Rev."},{"key":"2024093010302369900_DMM050836C90","doi-asserted-by":"publisher","first-page":"107522","DOI":"10.1016\/j.pharmthera.2020.107522","article-title":"Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights","volume":"210","author":"Meador","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"2024093010302369900_DMM050836C91","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/JTO.0000000000000468","article-title":"CSF concentration of crizotinib in two ALK-positive non\u2013small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment","volume":"10","author":"Metro","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"2024093010302369900_DMM050836C92","doi-asserted-by":"publisher","first-page":"v144","DOI":"10.1093\/noajnl\/vdab115","article-title":"Animal models of brain metastasis","volume":"3","author":"Miarka","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"2024093010302369900_DMM050836C93","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res"},{"key":"2024093010302369900_DMM050836C94","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s43018-023-00630-y","article-title":"Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations","volume":"4","author":"Miyazaki","year":"2023","journal-title":"Nat. Cancer"},{"key":"2024093010302369900_DMM050836C171","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"2024093010302369900_DMM050836C95","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.2006.09.9861","article-title":"Chemotherapy delivery issues in central nervous system malignancy: a reality check","volume":"25","author":"Muldoon","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C96","doi-asserted-by":"publisher","first-page":"v52","DOI":"10.1093\/noajnl\/vdab106","article-title":"Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies","volume":"3","author":"Myall","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"2024093010302369900_DMM050836C97","doi-asserted-by":"publisher","first-page":"379","DOI":"10.21037\/tlcr-22-638","article-title":"Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic lymphoma kinase (ALK)-positive disease","volume":"12","author":"Nelson","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"2024093010302369900_DMM050836C98","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.3390\/pharmaceutics13101542","article-title":"Drug penetration into the central nervous system: Pharmacokinetic concepts and in vitro model systems","volume":"13","author":"Neumaier","year":"2021","journal-title":"Pharmaceutics"},{"key":"2024093010302369900_DMM050836C99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-020-02867-z","article-title":"Impact of in vitro passive permeability in a P-gp-transfected LLC-PK1 model on the prediction of the rat and human unbound brain-to-plasma concentration ratio","volume":"37","author":"Nicola\u00ef","year":"2020","journal-title":"Pharm. Res."},{"key":"2024093010302369900_DMM050836C100","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","article-title":"Alectinib in crizotinib-refractory ALK-rearranged non\u2013small-cell lung cancer: a phase II global study","volume":"34","author":"Ou","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C101","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1042\/BJ20090387","article-title":"Anaplastic lymphoma kinase: signalling in development and disease","volume":"420","author":"Palmer","year":"2009","journal-title":"Biochem. J."},{"key":"2024093010302369900_DMM050836C102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.addr.2019.11.009","article-title":"The blood-brain barrier: Physiology and strategies for drug delivery","volume":"165","author":"Pandit","year":"2020","journal-title":"Adv. Drug Delivery. Rev."},{"key":"2024093010302369900_DMM050836C103","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1124\/mi.3.2.90","article-title":"Blood-brain barrier drug targeting: the future of brain drug development","volume":"3","author":"Pardridge","year":"2003","journal-title":"Mol. Interv."},{"key":"2024093010302369900_DMM050836C104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1602\/neurorx.2.1.1","article-title":"The blood-brain barrier and neurotherapeutics","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"2024093010302369900_DMM050836C105","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.lungcan.2012.05.092","article-title":"Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation","volume":"77","author":"Park","year":"2012","journal-title":"Lung Cancer"},{"key":"2024093010302369900_DMM050836C106","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non\u2013small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2024093010302369900_DMM050836C107","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1183\/09031936.00195609","article-title":"Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation","volume":"37","author":"Porta","year":"2011","journal-title":"Eur. Respir. J."},{"key":"2024093010302369900_DMM050836C108","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"2024093010302369900_DMM050836C109","doi-asserted-by":"publisher","first-page":"S1123","DOI":"10.1016\/j.jtho.2021.08.547","article-title":"P52. 03 efficacy of sotorasib in KRAS p. G12C-mutated NSCLC with stable brain metastases: a post-hoc analysis of CodeBreaK 100","volume":"16","author":"Ramalingam","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"2024093010302369900_DMM050836C110","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"2024093010302369900_DMM050836C111","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00280-019-04021-y","article-title":"Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma","volume":"85","author":"Rodgers","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2024093010302369900_DMM050836C112","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol. Res."},{"key":"2024093010302369900_DMM050836C113","doi-asserted-by":"publisher","first-page":"LBA9009-LBA9009","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA9009","article-title":"Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial","volume":"40","author":"Sabari","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C114","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1158\/1078-0432.CCR-22-0383","article-title":"Activity of Adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non\u2013small cell lung cancer","volume":"28","author":"Sabari","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"2024093010302369900_DMM050836C115","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.nec.2020.06.001","article-title":"Epidemiology of brain metastases","volume":"31","author":"Sacks","year":"2020","journal-title":"Neurosurg. Clin. N Am."},{"key":"2024093010302369900_DMM050836C116","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood\u2013brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol."},{"key":"2024093010302369900_DMM050836C117","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","article-title":"First-line afatinib versus chemotherapy in patients with non\u2013small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases","volume":"11","author":"Schuler","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"2024093010302369900_DMM050836C118","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jneumeth.2013.10.002","article-title":"Imaging and histological characterization of a human brain xenograft in pig: the first induced glioma model in a large animal","volume":"221","author":"Selek","year":"2014","journal-title":"J. Neurosci. Methods"},{"key":"2024093010302369900_DMM050836C119","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non\u2013small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2024093010302369900_DMM050836C120","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol."},{"key":"2024093010302369900_DMM050836C121","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"2024093010302369900_DMM050836C122","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2024093010302369900_DMM050836C123","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.addr.2004.07.011","article-title":"Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics","volume":"56","author":"Shen","year":"2004","journal-title":"Adv. Drug Delivery. Rev."},{"key":"2024093010302369900_DMM050836C124","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"2024093010302369900_DMM050836C125","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p. G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":". N. Engl. J. Med."},{"key":"2024093010302369900_DMM050836C126","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1200\/JCO.2015.63.5888","article-title":"Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014","volume":"34","author":"Solomon","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C127","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"key":"2024093010302369900_DMM050836C128","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non\u2013small-cell lung cancer from the phase III CROWN study","volume":"40","author":"Solomon","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C129","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2024093010302369900_DMM050836C170","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jpba.2018.08.038","article-title":"Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates","volume":"161","author":"Sparidans","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"2024093010302369900_DMM050836C130","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C131","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial efficacy of selpercatinib in RET fusion-positive non\u2013small cell lung cancers on the LIBRETTO-001 trial","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2024093010302369900_DMM050836C132","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11095-022-03172-7","article-title":"Free drug theory\u2013no longer just a hypothesis?","volume":"39","author":"Summerfield","year":"2022","journal-title":"Pharm. Res."},{"key":"2024093010302369900_DMM050836C133","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1517\/17425255.4.4.395","article-title":"The Caco-2 cell monolayer: usefulness and limitations","volume":"4","author":"Sun","year":"2008","journal-title":"Expert Opin Drug Metab. Toxicol."},{"key":"2024093010302369900_DMM050836C134","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1124\/dmd.108.024745","article-title":"Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport","volume":"37","author":"Syv\u00e4nen","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"2024093010302369900_DMM050836C135","doi-asserted-by":"publisher","first-page":"98771","DOI":"10.18632\/oncotarget.21936","article-title":"Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model","volume":"8","author":"Tan","year":"2017","journal-title":"Oncotarget"},{"key":"2024093010302369900_DMM050836C136","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jtho.2021.08.009","article-title":"Brain metastases in EGFR-and ALK-positive NSCLC: outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation","volume":"17","author":"Thomas","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"2024093010302369900_DMM050836C137","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","article-title":"Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer","volume":"70","author":"Togashi","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2024093010302369900_DMM050836C138","doi-asserted-by":"publisher","first-page":"102070","DOI":"10.1016\/j.ctrv.2020.102070","article-title":"KRAS: From undruggable to a druggable Cancer Target","volume":"89","author":"Uprety","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"2024093010302369900_DMM050836C139","doi-asserted-by":"publisher","first-page":"104297","DOI":"10.1016\/j.phrs.2019.104297","article-title":"Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)","volume":"146","author":"van Hoppe","year":"2019","journal-title":"Pharmacol. Res."},{"key":"2024093010302369900_DMM050836C140","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/jps.24301","article-title":"Exploring in silico prediction of the unbound brain-to-plasma drug concentration ratio: model validation, renewal, and interpretation","volume":"104","author":"Varadharajan","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"2024093010302369900_DMM050836C141","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1124\/dmd.106.013953","article-title":"Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures","volume":"35","author":"Venkatakrishnan","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"2024093010302369900_DMM050836C142","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C143","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/10826070701190989","article-title":"High throughput screening of drug-protein binding in drug discovery","volume":"30","author":"Wan","year":"2007","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"2024093010302369900_DMM050836C144","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/acs.molpharmaceut.5b00168","article-title":"Factors governing P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier measured with positron emission tomography","volume":"12","author":"Wanek","year":"2015","journal-title":"Mol. Pharm."},{"key":"2024093010302369900_DMM050836C145","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.tranon.2018.07.003","article-title":"Efficacy and safety of radiotherapy plus EGFR-TKIs in NSCLC patients with brain metastases: a meta-analysis of published data","volume":"11","author":"Wang","year":"2018","journal-title":"Transl. Oncol."},{"key":"2024093010302369900_DMM050836C146","doi-asserted-by":"publisher","first-page":"105850","DOI":"10.1016\/j.phrs.2021.105850","article-title":"ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib","volume":"172","author":"Wang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"2024093010302369900_DMM050836C147","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3390\/ph14111087","article-title":"P-glycoprotein (Abcb1\/mdr1) and bcrp (abcg2) limit brain accumulation and cytochrome p450-3a (cyp3a) restricts oral exposure of the ret inhibitor selpercatinib (retevmo)","volume":"14","author":"Wang","year":"2021","journal-title":"Pharmaceuticals"},{"key":"2024093010302369900_DMM050836C148","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1016\/j.cllc.2019.02.009","article-title":"Intracranial responses to afatinib at different doses in patients with EGFR-mutated non\u2013small-cell lung carcinoma and brain metastases","volume":"20","author":"Wei","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"2024093010302369900_DMM050836C149","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40262-016-0440-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of afatinib","volume":"56","author":"Wind","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"2024093010302369900_DMM050836C150","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2119\/molmed.2015.00207","article-title":"Blood-brain Barrier Remodeling during Brain Metastasis Formation","volume":"22","author":"Wrobel","year":"2016","journal-title":"Mol. Med."},{"key":"2024093010302369900_DMM050836C151","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/annonc\/mds529","article-title":"Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG\u20130803)","volume":"24","author":"Wu","year":"2013","journal-title":"Ann. Oncol."},{"key":"2024093010302369900_DMM050836C152","doi-asserted-by":"publisher","first-page":"9001","DOI":"10.1200\/JCO.2023.41.16_suppl.9001","article-title":"Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFR m+) non\u2013small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis","volume":"41","author":"Wu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C153","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/btm2.10108","article-title":"Method of establishing breast cancer brain metastases affects brain uptake and efficacy of targeted, therapeutic nanoparticles","volume":"4","author":"Wyatt","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"2024093010302369900_DMM050836C154","doi-asserted-by":"publisher","first-page":"368ra172","DOI":"10.1126\/scitranslmed.aag0976","article-title":"AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases","volume":"8","author":"Yang","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"2024093010302369900_DMM050836C155","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation\u2013positive non\u2013small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"2024093010302369900_DMM050836C156","doi-asserted-by":"publisher","first-page":"8200","DOI":"10.1021\/acs.jmedchem.5b01073","article-title":"Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor","volume":"58","author":"Zeng","year":"2015","journal-title":"J. Med. Chem."},{"key":"2024093010302369900_DMM050836C157","doi-asserted-by":"publisher","first-page":"8366","DOI":"10.18632\/oncotarget.3187","article-title":"Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy","volume":"6","author":"Zeng","year":"2015","journal-title":"Oncotarget"},{"key":"2024093010302369900_DMM050836C158","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1208\/s12248-015-9757-1","article-title":"Multidrug resistance proteins (MRPs) and cancer therapy","volume":"17","author":"Zhang","year":"2015","journal-title":"AAPS J."},{"key":"2024093010302369900_DMM050836C159","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1021\/acs.molpharmaceut.6b00031","article-title":"Integrating in silico and in vitro approaches to predict drug accessibility to the central nervous system","volume":"13","author":"Zhang","year":"2016","journal-title":"Mol. Pharm."},{"key":"2024093010302369900_DMM050836C160","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/aps.2016.107","article-title":"Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice","volume":"38","author":"Zhang","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"2024093010302369900_DMM050836C161","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.21037\/jtd.2019.03.76","article-title":"Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis","volume":"11","author":"Zhang","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"2024093010302369900_DMM050836C162","doi-asserted-by":"publisher","first-page":"750031","DOI":"10.3389\/fphar.2021.750031","article-title":"Experimental study of almonertinib crossing the blood-brain barrier in EGFR-mutant NSCLC brain metastasis and spinal cord metastasis models","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"2024093010302369900_DMM050836C163","doi-asserted-by":"publisher","first-page":"105931","DOI":"10.1016\/j.phrs.2021.105931","article-title":"A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer","volume":"174","author":"Zhao","year":"2021","journal-title":"Pharmacol. Res."},{"key":"2024093010302369900_DMM050836C164","doi-asserted-by":"publisher","first-page":"100343","DOI":"10.1016\/j.jtocrr.2022.100343","article-title":"Response to pralsetinib observed in meningeal-metastatic EGFR-mutant NSCLC with acquired RET fusion: a brief report","volume":"3","author":"Zhao","year":"2022","journal-title":"JTO Clin. Res. Rep."}],"container-title":["Disease Models &amp; Mechanisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.050836\/3568474\/dmm050836.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.050836\/3568474\/dmm050836.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T10:30:43Z","timestamp":1727692243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.biologists.com\/dmm\/article\/17\/9\/dmm050836\/362210\/Preclinical-evaluation-of-targeted-therapies-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":167,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1242\/dmm.050836","relation":{},"ISSN":["1754-8403","1754-8411"],"issn-type":[{"value":"1754-8403","type":"print"},{"value":"1754-8411","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,1]]},"article-number":"dmm050836"}}